Cutaneous Drug Eruption after COVID-19 Vaccination

Abstract

The SARS-CoV-2 virus is a highly transmissible virus that has infected millions of people globally over the past year. In the United States alone, over 400,000 deaths have been reported due to COVID-19 infection [1]. In order to prevent further spread and severe infection, the Food and Drug Administration (FDA) has authorized emergency use of the Moderna COVID19 vaccine which has demonstrated an efficacy rate of 94.1% in preventing COVID-19 infection [2]. The current recommended administration schedule for the Moderna COVID-19 vaccine is a total of 2 doses, each given at an interval of 28 days apart. Despite its efficacy, adverse events and hypersensitivity reactions are still under evaluation with a few cases reported to date [3]. We report a case of a 40-year-old woman who exhibited a diffuse cutaneous eruption after receiving their first dose of the Moderna vaccine.